

Trust Board Report

Meeting Date:	30 th January 2017
Title:	100,000 Genomes Project
Executive Summary:	<p><u>Personalisation of Medicine in the NHS and the 100,000 Genomes Project.</u></p> <p>There are now 13 GMCs in England. Northern Ireland, Scotland and Wales are also going to be participating.</p> <p>The West Midlands GMC is the largest of these and RWT is working as a part of this hub based at University Hospital Birmingham to roll out Phase 2 of the Project recruiting patients from our diverse population to the Rare Disease and Cancer programmes.</p>
Action Requested:	Information Only
Report of:	Genomics Ambassador
Author: Contact Details:	Tel 01902 447146 c.hitchcock@nhs.net
Links to Trust Strategic Objectives	<p>1. To improve the culture of compassion, safety and quality in every department and service we offer. We will be a patient centred organisation in which everyone is clear about how we work and our assurance processes will reflect this.</p> <p>3. To proactively seek opportunities to improve health services in our local health economy through collaboration and supportive partnerships. We will find opportunities to engage with our partners including local authorities, primary care, other secondary services and others e.g. voluntary services.</p> <p>4. To have an effective, well integrated organisation which operates efficiently. We will drive effectiveness through quality improvement and efficiency using opportunities for integration including vertically or through the TSA model for Cannock.</p> <p>5. To maintain the financial health of the organisation and seek appropriate investment opportunities that enable further enhancement of patient services. We will operate as a balanced organisation (quality, finance, performance) to deliver financial savings to enable investments into patient services.</p>
Resource Implications:	<p>Genomics Ambassador funded by West Midlands Academic Health and Science Network (WMAHSN). Contract extended to November 2017.</p> <p>Band 2 Admin assistant funded till November 2017 by West Midlands Genomic Medicine Centre (WGMGC)</p> <p>Band 4 Project Assistant funded by NHS England (tba)</p> <p>Band 7 Team Manager funded by NHS England (tba)</p>
Equality and Diversity Assessment	Covered at National Level

Title: Trust Board Report

Risks: BAF/ TRR (describe risk and current risk score)	No risks held by RWT relating to the project at present
Public or Private: (with reasons if private)	Public
References: (eg from/to other committees)	
Appendices/ References/ Background Reading	http://www.genomicsengland.co.uk/the-100000-genomes-project/ http://www.expressandstar.com/news/local-news/2016/05/31/mystery-over-behavioural-problems-of-nile-seven/
NHS Constitution: (How it impacts on any decision-making)	In determining this matter, the Board should have regard to the Core principles contained in the Constitution of: <ul style="list-style-type: none"> ✚ Equality of treatment and access to services ✚ High standards of excellence and professionalism ✚ Service user preferences ✚ Cross community working ✚ Best Value ✚ Accountability through local influence and scrutiny

Background Details	
1	2016: RWT granted go live status for Rare Diseases in April 2016 and Cancers in June 2016. To date we have recruited a total of 105 participants (81 Rare Disease, 24 Cancer)
2	Rare Diseases: Initially started with a push from clinical genetics and Dr Helen Cox with paediatric patients. This support still continues but clinicians are now referring their own patients in areas such as paediatrics, renal, dermatology and cardiology
3	Cancers: Piloted by one consultant for breast cancers and has now extended to all consultants within the specialty. Those with Colorectal, bladder and lung cancers are now also being recruited. We are looking to open to renal and testicular cancers in the next month.
4	Transformation: The proactive input of many of those who have been involved in the initial stages of the project has enabled us to take the opportunity to transform some aspects of our work at the Trust. Pathology has been a primary site for this with the engagement of a porter specifically to collect fresh tissue samples from theatre to ensure timeframes are adhered to but also looking at the potential for speeding the time taken for histology on all cancer specimens. The communication between wards, theatre and pathology has improved. Nursing staff becoming more involved in identification of patients. Cross Trust working improving. Greater input between clinical geneticists and specialty consultants at the Trust.
5	Public and Patient involvement: In December we held our first meeting for Patients who had been involved in the 100,000 Genomes project. This gave them an opportunity to talk about the experience they had had, their hopes for the future and to provide feedback.
6	<p>Our Local Delivery Partners</p> <ul style="list-style-type: none"> ○ <u>Dudley Group NHS Foundation Trust:</u> Live with and recruiting to rare diseases. Aiming to commence cancer samples at the end of January in colorectal ○ <u>Walsall Healthcare NHS Trust</u> Progress has been slower than in other Trusts. ○ <u>Worcestershire Acute Hospitals Trust</u> The new Medical Director is happy to take the project forward and we hope that this will see them taking part within the next few months


7	<p>Training, Recruitment and the Consenting process</p> <p>Training now takes the form of a train the trainer approach nationally. This is led by Health Education England with the face to face content created by the West Midlands GMC. There are still CPD modules for the MSc in genomics as well as the full MSc available at Birmingham. There is also an Access course which is designed for those with an interest in finding out more about Genomics. Recruitment and consenting is consistent but it is being reviewed nationally and locally. The Trust has Jenny Borley the lead for the Heart Failure team who is identifying and consenting patients within cardiology, colorectal, urology and breast care nurse specialists are also identifying potential participants and informing them of the project and referring on to the Genomics Team. This means that they are also providing an informed approach for the patient. Within pre-op assessment, nursing staff have taken on some of the consenting in the absence of the Genomics Ambassador. This will be discussed as potential for incorporating into routine practice.</p>
8	<p>Recognition: The incredibly forward thinking teams and individuals who have been involved in this project so far should be acknowledged. They are ensuring the Trust does as much as possible to embed genomics as part of routine care for our patients. This includes staff from pathology, phlebotomy, pre-op assessment staff, theatre staff and the nurse specialists.</p>

RWT 100,000 Genomes Project -Current position

1. The targets are achievable as there are the patients / cancers – the rate limiting factor has been the workforce element to recruit
2. There is an opportunity for RWT to become the national leading LDP contributor to the cancer arm and as such NHSE would be very grateful and it would boost your reputation
3. You deliver the numbers then you will be positioned in a very good place to trial it with little/no financial risk to yourselves
4. These targets could be viewed as regional and therefore the numbers from Dudley, Walsall and Worcester could supplement the RWT numbers. Remember I am only aiming for 4 RD participants from each phase 3 LDP so if Dudley recruits 9 then that's 5 patients towards a regional total. If any phase 3 LDP can deliver cancer samples that would be massive achievement as I'm not including phase 3 trusts in the cancer trajectory so again this could support the RWT figures and be seen as a regional contribution.

	RD Samples		Ca Samples	
	Target	Performance	Target	Performance
Apr-16	2	6	0	0
May-16	4	0	0	0
Jun-16	6	6	0	0
Jul-16	8	17	6	2
Aug-16	10	19	6	3
Sep-16	10	8	6	0
Oct-16	10	7	12	3
Nov-16	10	9	12	10
Dec-16	10	7	12	4
Jan-17	20	7	24	3
Feb-17	20		24	
Mar-17	20		24	
Apr-17	20		30	
May-17	20		40	
Jun-17	20		50	
Jul-17	30		60	
Aug-17	30		80	
Sep-17	30		80	

The highlighted figures are in line with a bid for workforce support from NHSE, the delivery of these trajectories would enable us to accrue money to support the posts past the 12 months NHSE funding and potentially beyond the project.



A band 7 at midpoint is approx £46K

A band 4 at midpoint is approx £27K

NHSE are investing £73K in RWT which equates to 2086 samples. To put that into context if the Trust hits the minimum target trajectories as detailed for 2017-18 income will be £40K

	RD	Ca	Total	£
Apr-17	20	30	50	1750
May-17	20	40	60	2100
Jun-17	20	50	70	2450
Jul-17	30	60	90	3150
Aug-17	30	80	110	3850
Sep-17	30	80	110	3850
Oct-17	30	80	110	3850
Nov-17	30	80	110	3850
Dec-17	30	80	110	3850
Jan-18	30	80	110	3850
Feb-18	30	80	110	3850
Mar-18	30	80	110	3850
Total				£40,250.00